People news: Pfizer and GlaxoSmithKline

Share this article:
Pfizer named GSK's Dr. Yvonne Greenstreet SVP, head of medicines development for its Specialty Care Business Unit. Greenstreet spent 18 years at GSK, most recently as SVP chief of strategy, research and development, and led development of small molecules and biologics in several therapeutic areas, including musculoskeletal, immunology/inflammation, gastrointestinal, urology, ophthalmology and anti-infectives, and also headed clinical development and medical affairs for the firm's European business. She succeeds Dr. Michael Berelowitz, who is retiring after 14 years at Pfizer, and she will report to Geno Germano, president and general manager, Specialty Care Business Unit.

Slack and the International Society of Refractive Surgery named James Bradley Randleman, MD editor-in-chief of the Journal of Refractive Surgery. Dr. Randleman is an assistant professor in the Department of Ophthalmology at Emory University.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.